Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Core Scientific (CORZ) Equity Average (2021 - 2026)

Core Scientific has reported Equity Average over the past 6 years, most recently at -$1.1 billion for Q1 2026.

  • Quarterly results put Equity Average at -$1.1 billion for Q1 2026, down 81.2% from a year ago — trailing twelve months through Mar 2026 was -$1.1 billion (down 81.2% YoY), and the annual figure for FY2025 was -$952.9 million, down 23.75%.
  • Equity Average reached -$1.1 billion in Q1 2026 per CORZ's latest filing, down from -$1.1 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.2 billion in Q1 2022 and bottomed at -$1.2 billion in Q3 2025.
  • Median Equity Average over the past 5 years was -$507.8 million (2023), compared with a mean of -$445.1 million.
  • The largest annual shift saw Equity Average surged 1224.13% in 2022 before it crashed 265.72% in 2023.
  • Over 5 years, Equity Average stood at -$168.2 million in 2022, then plummeted by 202.0% to -$507.8 million in 2023, then plummeted by 74.24% to -$884.9 million in 2024, then decreased by 25.18% to -$1.1 billion in 2025, then dropped by 2.39% to -$1.1 billion in 2026.
  • Business Quant data shows Equity Average for CORZ at -$1.1 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$1.2 billion in Q3 2025.